Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibition in Hemodialysis (DAPA-HD)
2024-518591-31-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD), end-stage kidney disease (ESKD), kidney failure and 1 more comparing Dapagliflozin (Forxiga) with Placebo (2 arms). Primary endpoint: Change in left ventricular mass index to body surface area (LVMI [g/m²]) from baseline to 6 months. Planned start Dec 2024; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)end-stage kidney disease (ESKD)kidney failureleft ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on 2024-518591-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518591-31-00.